Asthma: Symptoms, Causes, Triggers and Complete Treatment Guide
- Dr. Tobias Kohler
- 2 days ago
- 9 min read
Asthma affects approximately 1 in 13 Americans — around 25 to 29 million people — making it one of the most common chronic conditions in the United States. It causes approximately 2 million emergency department visits, 500,000 hospitalizations, and nearly 5,000 deaths every year. Yet despite being highly treatable, studies consistently show that more than half of Americans with moderate-to-severe asthma do not have their symptoms under control — even when they have health insurance and regular doctor visits.
In 2026, asthma is no longer viewed as a single uniform disease. It is understood as a collection of distinct phenotypes — allergic asthma, non-allergic asthma, eosinophilic asthma, exercise-induced, occupational — each with different underlying biology and optimal treatment approaches. This precision medicine evolution has produced a new generation of highly targeted biologic therapies that are transforming outcomes for patients with severe, difficult-to-control asthma.
This complete guide covers what asthma is, how to recognise its symptoms and severity, what triggers it, how it is diagnosed, and the full stepwise 2026 treatment approach from inhalers to biologics.
The NHLBI provides comprehensive asthma information and patient resources at: https://www.nhlbi.nih.gov/health/asthma
What is Asthma? — The Airway Biology
Asthma is a chronic inflammatory condition of the airways — the tubes that carry air in and out of the lungs. Three interrelated processes cause the characteristic symptoms:
Airway inflammation:
The inner lining of the bronchial tubes becomes chronically inflamed — swollen, red, and producing excess mucus. In allergic asthma, this inflammation is driven by eosinophils and mast cells responding to allergen exposure. In non-allergic asthma, neutrophils and other immune cells play a greater role.
Bronchoconstriction:
The smooth muscle surrounding the airways contracts — narrowing the airway lumen. This is the component most immediately responsive to bronchodilator (reliever) medicines such as salbutamol (albuterol), which relax bronchial smooth muscle within minutes.
Airway hyperresponsiveness:
Asthmatic airways are abnormally sensitive — they react to stimuli that would not affect normal airways (cold air, exercise, strong smells, smoke, viral infections). This hyperresponsiveness is the defining physiological feature of asthma.
With repeated inflammation and poor control over time, structural changes to airway walls can occur — a process called airway remodelling — which may cause irreversible airflow limitation. This is why long-term controller treatment and good asthma control matter beyond just symptom relief.
Asthma Types and Phenotypes
Allergic asthma (most common — approximately 60% of cases):
Triggered by specific allergens — house dust mite, pet dander (cat and dog), pollen, mould, and cockroach allergen are the most common. Typically develops in childhood. Associated with other atopic conditions — allergic rhinitis (hay fever), eczema, and food allergies. Elevated blood eosinophils and IgE levels. Responds extremely well to inhaled corticosteroids (ICS) and targeted biologics (anti-IgE, anti-IL-5, anti-IL-4/13).
Non-allergic asthma:
Not driven by allergen sensitisation. More common in adults, particularly women. Triggered by viral infections, cold air, exercise, NSAIDs, or stress. May be harder to treat as it does not respond as predictably to ICS.
Eosinophilic asthma:
Characterised by elevated blood and airway eosinophils regardless of allergy status. Often adult-onset, more severe, and associated with nasal polyps and aspirin-exacerbated respiratory disease (AERD — Samter's triad). Responds dramatically to anti-IL-5 biologics (mepolizumab, benralizumab).
Exercise-induced bronchoconstriction (EIB):
Airway narrowing triggered specifically by exercise — typically 5–15 minutes after starting exercise. Common in competitive athletes and in patients with poorly controlled asthma. Pre-exercise short-acting bronchodilator (SABA) and warm-up protocols are effective management.
Occupational asthma:
Caused by workplace exposures — isocyanates (spray painters), flour and grain dust, latex, wood dust, animal proteins (laboratory workers, veterinarians). Removing the trigger often produces significant improvement; prolonged exposure worsens long-term prognosis.
Aspirin-exacerbated respiratory disease (AERD):
The triad of asthma + nasal polyps + aspirin/NSAID intolerance. Severe bronchoconstriction triggered by aspirin and non-selective NSAIDs within 30–120 minutes of ingestion. Aspirin desensitisation is a specialist management option.
Symptoms of Asthma
Core symptoms (the classic triad):
Wheezing — a high-pitched whistling sound during breathing, particularly on expiration; the most recognisable asthma symptom
Shortness of breath (dyspnoea) — difficulty breathing, feeling of breathlessness, or inability to complete sentences
Chest tightness — a sensation of constriction or pressure in the chest; often described as "a band around the chest"
Cough — particularly a dry, persistent cough that is worse at night or early morning; nocturnal cough is a key diagnostic clue
Symptom patterns typical of asthma:
Worse at night or early morning (when airway calibre is naturally at its narrowest)
Triggered or worsened by specific stimuli (allergens, exercise, cold air, viral infections)
Variable — symptoms fluctuate day to day and over weeks; this variability is characteristic
Partially or fully reversible with bronchodilator use — key distinguishing feature from COPD
Asthma attack (acute exacerbation) signs:
Rapid worsening of breathlessness, wheeze, cough, and chest tightness
SABA reliever (blue inhaler) needed more than 2–3 times per week for symptoms
Increasing frequency of night waking
Severe asthma attack — emergency signs (seek immediate medical help):
Inability to complete sentences due to breathlessness
Blue lips or fingertips (cyanosis)
Accessory muscle use (neck and abdominal muscles straining to breathe)
Silent chest — no wheeze heard (complete obstruction; a dangerous sign)
Confusion or drowsiness — severe hypoxia
Peak flow below 50% of personal best
Diagnosing Asthma
Asthma diagnosis is clinical and functional — based on a characteristic symptom history combined with objective evidence of variable airflow obstruction:
Spirometry:
The essential lung function test. Measures FEV1 (the volume of air exhaled in the first second of a forced exhalation) and FVC (total forced vital capacity). An FEV1/FVC ratio below 0.70 confirms airflow obstruction. Significant reversibility — FEV1 improvement of 12% or more and 200mL or more after a bronchodilator — confirms asthma-pattern reversibility.
Peak expiratory flow (PEF):
A simple handheld device measuring the maximum speed of exhalation. PEF variability of 20% or more between morning and evening readings (or before and after bronchodilator) is highly suggestive of asthma. Used for home monitoring and self-management via Asthma Action Plans.
Fractional exhaled nitric oxide (FeNO):
Measures airway eosinophilic inflammation — elevated in allergic and eosinophilic asthma. FeNO above 40 ppb strongly suggests eosinophilic airway inflammation and predicts good response to ICS and anti-IL-5 biologics. Increasingly used in 2026 to guide biologic selection.
Challenge tests:
Methacholine or mannitol challenge — provokes bronchoconstriction in patients with hyperresponsive airways; used when spirometry is normal but symptoms suggest asthma. Negative challenge test largely excludes asthma.
Allergy testing:
Skin prick tests or specific IgE blood tests (RAST/ImmunoCAP) identify specific allergen sensitisation — important for confirming allergic asthma and guiding avoidance advice and immunotherapy decisions.
Treatment — The 2026 GINA Stepwise Approach
The Global Initiative for Asthma (GINA) 2026 guidelines use a stepped treatment approach based on symptom control and exacerbation risk:
Step 1 (Mild intermittent asthma):
As-needed low-dose ICS-formoterol (the preferred reliever per GINA 2026 — replacing SABA-only approaches, as ICS-formoterol provides both relief and anti-inflammatory cover simultaneously). This is a major 2026 guideline change — SABA-only use for mild asthma is no longer recommended as first-line.
Step 2 (Mild persistent):
Regular low-dose ICS (inhaled corticosteroid) daily controller + as-needed ICS-formoterol reliever. ICS reduces airway inflammation and is the cornerstone of asthma management.
Step 3 (Moderate persistent):
Low-dose ICS-LABA (inhaled corticosteroid + long-acting beta-agonist) combination inhaler daily + as-needed reliever. LABAs (formoterol, salmeterol, vilanterol) maintain bronchodilation over 12–24 hours but must always be used with ICS in asthma — never as monotherapy due to safety concerns.
Step 4 (Severe persistent):
Medium or high-dose ICS-LABA + additional controller medicines (tiotropium LAMA, leukotriene receptor antagonists — montelukast). Referral to specialist.
Step 5 (Very severe / uncontrolled on high-dose ICS-LABA):
Add-on biologic therapies — the major advance of recent years — targeting specific inflammatory pathways:
Anti-IgE: Omalizumab (Xolair) — for allergic asthma with elevated IgE; proven to reduce exacerbations and oral steroid use
Anti-IL-5: Mepolizumab (Nucala), Reslizumab (Cinqair) — for eosinophilic asthma; reduces blood eosinophils and exacerbations
Anti-IL-5 receptor: Benralizumab (Fasenra) — depletes eosinophils rapidly; 8-weekly injection after loading
Anti-IL-4/IL-13: Dupilumab (Dupixent) — targets type 2 inflammation broadly; also treats eczema and nasal polyps; the most versatile Step 5 biologic in 2026
Anti-TSLP: Tezepelumab (Tezspire) — FDA-approved 2021; broadest mechanism — effective in both eosinophilic and non-eosinophilic severe asthma; the newest and most inclusive biologic
Bronchial thermoplasty — invasive bronchoscopic procedure reducing smooth muscle mass; reserved for severe refractory cases
Oral corticosteroids (OCS):
Used for acute exacerbations (prednisolone 40–50mg for 5 days) and as short bursts for severe flares. Long-term OCS should be avoided due to profound systemic side effects (adrenal suppression, diabetes, osteoporosis, cataracts, weight gain) — the biologics have dramatically reduced OCS dependence in severe asthma.
Asthma Inhaler Types Comparison
Inhaler Type | Examples | Role | Frequency | Key Notes |
SABA (short-acting beta agonist) | Salbutamol (albuterol), Levalbuterol | Rescue / reliever | As needed | Acts within 5 min; effects 4–6 hours; overuse signals poor control |
ICS (inhaled corticosteroid) | Beclometasone, Budesonide, Fluticasone, Ciclesonide | Controller — anti-inflammatory | Daily | Cornerstone of asthma management; rinse mouth after use |
ICS-LABA combination | Symbicort, Fostair, Seretide, Breo, Trelegy | Controller — Steps 3–4 | Daily | Never use LABA without ICS in asthma |
ICS-formoterol (MART) | Symbicort, Fostair | Controller + Reliever (GINA 2026) | Daily + as needed | Single inhaler maintenance and reliever therapy — new 2026 standard |
LAMA (long-acting muscarinic antagonist) | Tiotropium (Spiriva Respimat) | Add-on controller — Step 4+ | Daily | Also used in COPD; bronchodilation via different mechanism |
LTRA (leukotriene receptor antagonist) | Montelukast | Add-on controller | Daily (oral tablet) | Also treats allergic rhinitis; less effective than ICS alone |
Anti-IgE biologic | Omalizumab (Xolair) | Step 5 — allergic asthma | Every 2–4 weeks (injection) | Requires elevated IgE and allergen sensitisation |
Anti-IL-5 biologic | Mepolizumab (Nucala), Benralizumab (Fasenra) | Step 5 — eosinophilic asthma | Every 4–8 weeks (injection) | Requires elevated eosinophils |
Anti-IL-4/13 biologic | Dupilumab (Dupixent) | Step 5 — type 2 inflammation | Every 2 weeks (injection) | Broadest use; also treats eczema, nasal polyps |
Anti-TSLP biologic | Tezepelumab (Tezspire) | Step 5 — all phenotypes | Every 4 weeks (injection) | Works in eosinophilic AND non-eosinophilic; most inclusive |
Asthma Triggers — Avoidance Table
Trigger | How It Causes Symptoms | Avoidance Strategy |
House dust mite | IgE-mediated allergic inflammation | Allergen-proof mattress/pillow covers; hot washing of bedding |
Cat and dog dander | Potent allergen; stays airborne for hours | Remove pet from bedroom; HEPA air filters |
Pollen (tree, grass, weed) | Seasonal allergen — inhaled | Monitor pollen counts; keep windows closed on high days |
Mould and dampness | Fungal spores trigger inflammation | Fix leaks; dehumidifier; avoid composting areas |
Exercise | Triggers EIB via airway drying/cooling | Pre-exercise SABA; warm-up 10–15 min; scarf in cold |
Cold air | Direct airway stimulus | Breathe through nose; scarf over mouth outdoors |
Viral respiratory infections | Major exacerbation trigger | Annual influenza vaccine; COVID vaccination |
Tobacco smoke (active + passive) | Powerful irritant; worsens airway inflammation | Complete smoke avoidance; stop smoking support |
NSAIDs / Aspirin | Triggers AERD in susceptible patients | Use paracetamol instead; test with COX-2 inhibitors |
Occupational exposures | Isocyanates, flour, latex, animals | Respiratory protection; consider job change if sensitised |
Stress and strong emotions | Hyperventilation; HPA axis activation | Stress management; breathing techniques |
Gastro-oesophageal reflux (GORD) | Acid micro-aspiration worsens airways | PPI therapy; lifestyle modification |
For our complete guide on allergic rhinitis — which coexists with asthma in up to 80% of patients and worsens asthma control: [Hydroxychloroquine for Lupus and Rheumatoid Arthritis]
For our guide on obesity — which significantly worsens asthma severity and reduces inhaler effectiveness: [Obesity: Causes, Health Risks and Treatment]
For our guide on depression and anxiety — both significantly more common in asthma patients and affecting adherence: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
Full NHLBI asthma treatment guidance and Asthma Action Plan resources: https://www.nhlbi.nih.gov/health/asthma/treatment-action-plan
CDC asthma surveillance, statistics, and patient resources: https://www.cdc.gov/asthma/index.html
Frequently Asked Questions
Can asthma go away on its own?
Asthma symptoms can vary significantly over time — some children with asthma appear to outgrow it during adolescence as their airways grow, though lung function studies often show persistent underlying hyperresponsiveness. In adults, asthma rarely resolves completely. However, with excellent treatment and trigger control, many patients achieve complete symptom control — no symptoms, no night waking, no limitation on activities — which can feel equivalent to being asthma-free. Long periods without symptoms can lead patients to stop treatment, which often causes symptoms to return.
What is the difference between asthma and COPD?
Both asthma and COPD cause airflow obstruction and similar symptoms — wheezing, breathlessness, and cough — but they differ fundamentally. Asthma typically begins in childhood, is associated with allergy, and shows fully reversible airflow obstruction that returns to normal between attacks. COPD is almost always caused by cigarette smoking, typically develops after age 40, and involves progressive, largely irreversible airflow limitation. Some patients have both conditions simultaneously — called asthma-COPD overlap (ACO). A key practical difference: asthma responds dramatically to inhaled corticosteroids; COPD has a much more modest response.
Is it safe to use an inhaler every day long-term?
Yes — inhaled corticosteroids (ICS) are safe for long-term daily use at the doses used in asthma management. Unlike oral corticosteroids, inhaled steroids deliver medication directly to the airways in tiny doses, minimising systemic absorption. The main local side effects are oral thrush (candidiasis) and hoarseness — both prevented by rinsing the mouth with water after each use and using a spacer device. The risk of long-term ICS use is far outweighed by the risk of uncontrolled asthma — severe asthma attacks, airway remodelling, and respiratory failure.
Can exercise trigger asthma and should I avoid it?
Exercise is a common asthma trigger — exercise-induced bronchoconstriction (EIB) affects up to 90% of asthma patients. However, avoiding exercise is NOT the recommended approach. Regular aerobic exercise improves overall cardiovascular fitness, reduces body weight (which improves asthma control), and may reduce airway hyperresponsiveness over time. The recommended strategy is to optimise background asthma control with ICS, use a short-acting bronchodilator (SABA) 10–15 minutes before exercise, and warm up gradually. With good control, most asthma patients can exercise without limitation.
When should asthma patients use their blue reliever inhaler?
A SABA reliever inhaler (blue inhaler — salbutamol/albuterol) should be used to relieve symptoms as they occur. Using it more than 2 to 3 times per week for symptom relief is a sign that asthma is not well controlled and that the controller (preventer) treatment needs to be stepped up. Under GINA 2026 guidelines for mild asthma, low-dose ICS-formoterol combination inhalers are now preferred over SABA-only as the reliever — providing both immediate bronchodilation and anti-inflammatory cover with each use. Overreliance on a SABA reliever without adequate controller therapy is associated with worse outcomes including fatal asthma attacks.
Comments